J.W. Cole Advisors Inc. Grows Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

J.W. Cole Advisors Inc. increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 11.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 802 shares of the biopharmaceutical company’s stock after purchasing an additional 83 shares during the quarter. J.W. Cole Advisors Inc.’s holdings in Regeneron Pharmaceuticals were worth $843,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in REGN. Frank Rimerman Advisors LLC lifted its stake in shares of Regeneron Pharmaceuticals by 3.5% in the third quarter. Frank Rimerman Advisors LLC now owns 597 shares of the biopharmaceutical company’s stock worth $628,000 after buying an additional 20 shares in the last quarter. Clear Harbor Asset Management LLC lifted its stake in Regeneron Pharmaceuticals by 0.9% in the 3rd quarter. Clear Harbor Asset Management LLC now owns 2,415 shares of the biopharmaceutical company’s stock worth $2,539,000 after purchasing an additional 21 shares in the last quarter. NorthCrest Asset Manangement LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 2.5% during the 3rd quarter. NorthCrest Asset Manangement LLC now owns 11,076 shares of the biopharmaceutical company’s stock worth $11,644,000 after purchasing an additional 271 shares during the last quarter. Forsta AP Fonden grew its position in shares of Regeneron Pharmaceuticals by 9.9% in the third quarter. Forsta AP Fonden now owns 24,500 shares of the biopharmaceutical company’s stock valued at $25,755,000 after purchasing an additional 2,200 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Regeneron Pharmaceuticals by 19.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 45,581 shares of the biopharmaceutical company’s stock valued at $46,904,000 after purchasing an additional 7,428 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Trading Down 0.1 %

NASDAQ REGN opened at $927.33 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $772.84 and a 12 month high of $1,211.20. The company has a market capitalization of $102.23 billion, a price-to-earnings ratio of 24.56, a price-to-earnings-growth ratio of 3.20 and a beta of 0.12. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. The firm’s fifty day moving average price is $1,077.78 and its 200 day moving average price is $1,041.48.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, beating the consensus estimate of $8.93 by $2.63. The business had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The business’s quarterly revenue was up 12.3% on a year-over-year basis. During the same period in the previous year, the business earned $8.79 EPS. On average, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.6 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

REGN has been the topic of a number of recent research reports. Wells Fargo & Company lowered their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 22nd. Guggenheim raised their price objective on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Royal Bank of Canada reiterated an “outperform” rating and issued a $1,260.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, October 22nd. Morgan Stanley cut their price target on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $1,101.00.

Insider Activity

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of the firm’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the transaction, the vice president now directly owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Jason Pitofsky sold 487 shares of the company’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the transaction, the vice president now owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 7.48% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.